Akero Therapeutics Inc · Q3 2024 earnings

Briefing

Akero Therapeutics reported financial results for the third quarter of 2024 and provided business updates.

Akero Therapeutics reported cash, cash equivalents and short and long-term marketable securities of $787.1 million as of September 30, 2024. The first patient was dosed in the Phase 3 SYNCHRONY Outcomes study.

• First patient dosed in Phase 3 SYNCHRONY Outcomes study of EFX in patients with compensated cirrhosis (F4) due to MASH.
• Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027.
• Phase 2b SYMMETRY study week 96 results expected to readout in February 2025.
• Current cash, cash equivalents, and short- and long-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through readout of their respective primary endpoints and Akero’s current operating plan into the second half of 2027.

Headline financials

Revenue & EPS history

Akero believes that its current cash, cash equivalents, and short- and long-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through readout of their respective primary endpoints and Akero’s current operating plan into the second half of 2027.